bioAffinity Technologies Inc. (NASDAQ: BIAF) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT BIOAFFINITY TECHNOLOGIES INC.

bioAffinity Technologies Inc. (NASDAQ: BIAF)
Listen to this Section


$0.85
+0.0132 ( +1.59% ) 578.1K

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Market Data


Open $0.85
Previous Close $0.83
Volume 578.1K
Market Cap $3.95M
Day Range $0.81 - $0.87
52 Week Range $0.69 - $13.80
Shares Outstanding 4.74M
Change % +1.59%
Net Change ▲ 0.0132
Insider Ownership -0.01%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
IPO Year2022
CountryUnited States
UnderwriterWallachBeth Capital, Craft Capital Management, more

Insider Ownership Transactions

Total Amount Purchased: -874,267.00

Date Type Amount Purchased Purchaser
2024-03-29 Sale -64848.00 Anderson Robert A.
2024-02-02 Sale -6688.00 Zannes Timothy P
2024-02-02 Sale -31847.00 Dougherty Michael Philip
2024-02-02 Sale -11943.00 GIRGENTI STEVEN
2024-02-02 Sale -31847.00 Rebel Vivienne I
2024-02-02 Sale -16720.00 Reveles Xavier Trinidad
2024-02-02 Sale -23885.00 Zannes Maria
2024-01-24 Sale -11867.00 DIAMOND STUART
2024-01-24 Sale -11867.00 Joyce Roby
2024-01-24 Sale -12668.00 Platt Jamie

SEC Filings


Form Type Description Pages Date
8-k 8K-related 15 Apr 07, 2026
8-k 8K-related 14 Apr 01, 2026
8-k 8K-related 34 Mar 26, 2026
8-k 8K-related 15 Mar 25, 2026
8-k 8K-related 14 Mar 17, 2026
10-k Annual reports 89 Mar 16, 2026
def Proxies and info statements 19 Mar 16, 2026
8-k 8K-related 15 Mar 13, 2026
8-k 8K-related 15 Mar 10, 2026
8-k 8K-related 13 Mar 06, 2026

Latest News


× Before browsing our site, please accept our cookies policy